INTRODUCTION
Inclusion body myositis (IBM) is an acquired myopathy of both inflammatory and degenerative nature with an increased incidence in elderly and male patients. It is a rare condition with an unclear etiology, occurring with neurodegenerative findings in addition to a cytotoxic T cell-mediated immune response (1). Although several factors have been associated with the development of IBM, tyrosine kinase inhibitors seems safer in that issue and only one case of IBM developed after the use of dasatinib has been reported so far (2). Here, we report a case of IBM, associated with the prolonged use of imatinib which is the first case in literature.